Leming v. Secretary of Health and Human Services

United States Court of Federal Claims·Decided July 1, 2021·No. 18-232·Published

Opinion

In the United States Court of Federal Claims (Filed Under Seal: June 16, 2021 | Reissued for Publication: July 1, 2021) *

)

VICTORIA LEMING and KEVIN LEMING, ) Parents and Natural Guardians of A.L., ) A Minor, )

) No. 18-232V Petitioners, )

)

v. )

)

SECRETARY OF HEALTH AND HUMAN ) SERVICES, )

)

Respondent. )

)

Robert J. Krakow, Law Office of Robert J. Krakow, P.C., New York, NY, for Petitioner.

Julia M. Collison, Trial Attorney, Torts Branch, Civil Division, U.S. Department of Justice, Washington, DC, with whom were Alexis B. Babcock, Assistant Director, Heather L. Pearlman, Acting Deputy Director, C. Salvatore D’Alessio, Acting Director, and Brian M. Boynton, Acting Assistant Attorney General, for Respondent.

OPINION AND ORDER

KAPLAN, J.

This case, which arises under the National Childhood Vaccine Injury Act of 1986, 42 U.S.C. §§ 300aa-1 to -34 (“Vaccine Act” or “the Act”), is before the Court on a motion for review filed by the Secretary of Health and Human Services (“the Secretary”). The Secretary challenges Special Master Nora B. Dorsey’s ruling that a bone aspiration performed along with a biopsy to determine the proper treatment for petitioner A.L.’s vaccine-related injury was a “surgical intervention” for purposes of 42 U.S.C. § 300aa-11(c)(1)(D)(iii). The government contends that the Special Master’s interpretation of the statutory language was legally erroneous and that additionally—because A.L.’s injury did not last more than six months, id. § 300aa-11(c)(1)(D)(i), nor result in her death, id. § 300aa-11(c)(1)(D)(ii)—her injury was not severe enough to satisfy the Act’s minimum eligibility threshold.

*

Pursuant to Vaccine Rule 18(b), this opinion was initially filed on June 16, 2021, and the parties were afforded fourteen days to propose redactions. The parties did not propose any redactions and, accordingly, this Opinion is reissued in its original form for publication.

For the reasons set forth below, the Court concludes that the Special Master’s decision was contrary to law. While the bone aspiration was a surgical procedure, it was not a surgical “intervention.” Id. § 300aa-11(c)(1)(D)(iii). The Secretary’s motion for review, ECF No. 75, is therefore GRANTED.

BACKGROUND

I. A.L.’s Vaccine and Hospitalization

On September 6, 2016, during a scheduled well-child visit, fifteen-month-old A.L.

received the measles-mumps-rubella-varicella (MMRV) vaccine, the diphtheria-tetanus-acellular pertussis (DTaP) vaccine, and the Haemophilus influenzae type b (Hib) vaccine. Pet’r’s Ex. 1 at 37–39, ECF No. 5-1. Within the next week, A.L. developed a rash and fever. Pet’r’s Ex. 13 at 3, ECF No. 24-1. A.L.’s mother reported the rash to the pediatrician on September 16, 2016. Id. By this point, A.L. no longer had a fever, and she was sleeping and eating normally. Id. The pediatrician told A.L.’s mother that the rash was likely roseola and that no treatment was needed. Pet’r’s Ex. 8 at 214, ECF No. 5-8.

A few days later, however, on September 29, 2016, A.L. presented to the emergency room with a petechial 1 rash on her body and tongue, and bleeding gums. Id. at 215. A blood test revealed a low platelet count. Id.

A.L. was admitted to the hospital and administered one dose of intravenous (“IV”)

immunoglobulin. Id. 2 After A.L. received the treatment, she exhibited increased bruising and the next day, on September 30, 2016, was transferred to Children’s Hospital in Omaha. Id. She received a second dose of IV immunoglobulin at Children’s Hospital and again showed no improvement. Pet’r’s Ex. 4 at 16, ECF No. 5-4.

On October 1, A.L.’s consulting physician, Dr. Stefanie Lowas, recorded that immune thrombocytopenia purpura (“ITP”) was the “most likely” explanation for A.L.’s symptoms, but that other diagnoses, albeit “very unlikely” ones, “could include congenital platelet disorders, acquired bone marrow failure, and leukemia.” Id. at 21. 3 Dr. Lowas commented that, while “IV

1 Petechiae are small pinpoint skin rashes that can arise due to insufficient platelets. See Dorland’s Illustrated Medical Dictionary 1401 (33d ed. 2020) (explaining that petechiae are “purplish red spot[s] caused by intradermal or submucous hemorrhage”). 2 IV immunoglobulin is antibody-containing solution derived from plasma that is used to treat patients with antibody deficiencies and autoimmune diseases. S. Jolles, W.A.C. Sewell & S.A. Misbah, Clinical Uses of Intravenous Immunoglobulin, 142(1) Clinical & Experimental Immunology (2005), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1809480/. 3 ITP “is a disorder that can lead to easy or excessive bruising and bleeding [which] results from unusually low levels of platelets.” Immune thrombocytopenia (ITP), Mayo Clinic, https://www.mayoclinic.org/diseases-conditions/idiopathic-thrombocytopenicpurpura/symptomscauses /syc-20352325; see also 42 C.F.R. § 100.3(c)(7) (characterizing thrombocytopenic

[immunoglobulin] serves as a very good diagnostic and therapeutic measure for ITP, it may be ineffective in about 25% of patients with ITP.” Id. For these patients, she explained, “[t]here are numerous other treatment options,” but an ITP “diagnosis should be confirmed before any of these are given.” Id. Dr. Lowas recommended that, if A.L.’s platelet count did not increase within the next two or three days, A.L. receive a “bone marrow aspirate/biopsy to rule out bone marrow disorders” and that “[a]fter that, other ITP therapies may be considered.” Id.

In fact, A.L.’s platelet count did not improve over the next several days. As a result, and consistent with Dr. Lowas’ recommendation, her treating physician, Dr. James Harper, agreed that A.L. “should have a bone marrow aspirate and biopsy to [rule out other diagnoses] before starting steroids.” Id. at 53.

On October 4, 2016, Dr. Harper completed a preoperative checklist, id. at 74, and placed A.L. under general anesthesia, id. at 80. He conducted a bone marrow needle aspiration and biopsy. Id. at 79–81. 4 The procedure yielded no evidence of cancer or other blood cell disorders. Id. at 117. Dr. Harper therefore concluded that there was no contraindication to A.L. starting IV steroid treatment for her ITP. Id. at 52.

A.L. thereafter received steroid treatment which was effective and resulted in an improvement in her platelet count. Id. at 4. As a consequence, A.L. was discharged from the hospital on October 12, 2016. Id. at 3–5. A follow-up examination was conducted on December 30, 2016, almost four months after A.L. received the vaccinations. Pet’r’s Ex. 9 at 60–67, ECF No. 5-9. A.L.’s hematologist reported that her platelet counts were normal, and that she suffered from no other remaining symptoms. Id. at 60–61. In addition, a pediatric immunologist determined that A.L.’s ITP episode had resolved and that there was no need for further treatment. Pet’r’s Ex. 10 at 9, ECF No. 5-10.

II. The Vaccine Claim and the Special Master’s Ruling on Facts

On February 14, 2018, A.L.’s parents, Victoria and Kevin Leming, filed a petition for compensation pursuant to the National Vaccine Injury Compensation Program, 42 U.S.C. § 300aa-1 to -34. In their petition, the Lemings alleged that the vaccines that A.L. received on September 6, 2016 caused her to experience immune thrombocytopenic purpura, immune dysfunction, and immunodeficiency. Pet. for Comp. Under the Vaccine Act at 1, ECF No. 1.

purpura as “the presence of clinical manifestations, such as petechiae, significant bruising, or spontaneous bleeding, and by a serum platelet count less than 50,000/mm3”). 4 The procedure to conduct a bone marrow aspiration and biopsy require that a child be sedated—occasionally with general anesthesia—and that specialized needles then be used to remove samples of bone and marrow from the child’s hip area. Oussama Abla, Jeremy Friedman & John Doyle, Performing bone marrow aspiration and biopsy in children: Recommended guidelines, 13(6) Paediatrics & child health 499–501 (2008), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2532899/.

Free access — add to your briefcase to read the full text and ask questions with AI

Leming v. Secretary of Health and Human Services, (uscfc 2021).

Leming v. Secretary of Health and Human Services (Leming v. Secretary of Health and Human Services) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Moberly v. Secretary of Health & Human Services
592 F.3d 1315 (Federal Circuit, 2010)
Greenleaf v. Goodrich
101 U.S. 278 (Supreme Court, 1880)
Corning Glass Works v. Brennan
417 U.S. 188 (Supreme Court, 1974)
Chrysler Corp. v. Brown
441 U.S. 281 (Supreme Court, 1979)
Park 'N Fly, Inc. v. Dollar Park & Fly, Inc.
469 U.S. 189 (Supreme Court, 1985)
Williams v. Taylor
529 U.S. 420 (Supreme Court, 2000)
Broekelschen v. Secretary of Health & Human Services
618 F.3d 1339 (Federal Circuit, 2010)
Groff v. United States
493 F.3d 1343 (Federal Circuit, 2007)
Myore v. Nicholson
489 F.3d 1207 (Federal Circuit, 2007)
Althen v. Secretary of Health and Human Services
418 F.3d 1274 (Federal Circuit, 2005)
Cloer v. Secretary of Health and Human Services
654 F.3d 1322 (Federal Circuit, 2011)
Henry P. Nichols v. Department of Veterans Affairs
11 F.3d 160 (Federal Circuit, 1993)
Telecare Corp. v. Leavitt
409 F.3d 1345 (Federal Circuit, 2005)
Exxon Mobil Corp. v. Allapattah Services, Inc.
545 U.S. 546 (Supreme Court, 2005)
Carson v. Secretary of Health & Human Services
727 F.3d 1365 (Federal Circuit, 2013)